STORM Therapeutics, a Cambridge-based biotechnology firm, has successfully secured $56 million (€47.5 million) in a Series C financing round. The funding, provided by a syndicate of existing investors including M Ventures and Pfizer Ventures, is earmarked for advancing the company's lead cancer therapy candidate, STC-15. This capital will specifically support the progression of STC-15 into a Phase 2 clinical trial for treating selected sarcoma indications.
Advancing a Novel Cancer Therapy
The company's lead candidate, STC-15, is a pioneering first-in-class oral inhibitor targeting the METTL3 enzyme. It holds the distinction of being the first RNA-modifying enzyme inhibitor to advance into human clinical studies. STORM has already commenced the Phase 2 trial, successfully dosing the first patient in the study focused on sarcoma.
Jerry McMahon, CEO of STORM Therapeutics, described the advancement into Phase 2 as a pivotal breakthrough for cancers with aberrant cell differentiation. He emphasized the company's scientific innovation and its potential to create new therapeutic options for patients with significant unmet needs. McMahon also expressed gratitude for the steadfast support from investors, which enables this critical next step.
Targeting the Root of Sarcoma
STC-15's novel mechanism of action targets sarcomas by inhibiting METTL3, an enzyme integral to regulating cancer stem cell differentiation. This process is critical in the development and progression of sarcomas and other forms of cancer. By disrupting this pathway, the therapy aims to reprogram malignant cells and halt their growth.
Sarcomas are cancers that originate in bone or soft tissues and account for 15% of pediatric cancers. These malignancies often lack the driver mutations or immunogenic features that make them responsive to standard treatments. Consequently, they rely heavily on METTL3-driven methylation for their growth and survival, making it a key therapeutic target.
Promising Early Results and Future Outlook
The decision to advance STC-15 was bolstered by encouraging data from its Phase 1 monotherapy study. The trial demonstrated durable tumor regression across multiple subtypes of sarcoma, underscoring its potential to reprogram progenitor cells. These promising results are scheduled to be presented at a major medical conference in 2026.
The current Phase 2 study is strategically designed to support a potential accelerated regulatory approval pathway for STC-15. Beyond its primary focus on sarcoma, the trial aims to establish a solid foundation for subsequent clinical development. This could pave the way for investigating STC-15's efficacy across a broader range of oncology indications.
This substantial $56 million investment marks a significant vote of confidence in STORM Therapeutics' innovative approach to cancer treatment. The funding not only accelerates the development of STC-15 but also reinforces the growing importance of epitranscriptomics in oncology. If successful, this novel therapy could offer a vital new treatment paradigm for sarcoma patients worldwide.